Company Description
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States.
The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.
It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy.
The company is based in Carlsbad, California.
| Country | United States |
| Founded | 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | J. D. Finley |
Contact Details
Address: 7750 El Camino Real, Suite 5200 Carlsbad, California 92009 United States | |
| Phone | (858) 704-4900 |
| Website | palisadebio.com |
Stock Details
| Ticker Symbol | PALI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001357459 |
| CUSIP Number | 696389105 |
| ISIN Number | US6963892046 |
| Employer ID | 52-2007292 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| J. D. Finley | Chief Executive Officer, Chief Financial Officer and Director |
| Dr. Mitchell Lawrence Jones M.D., Ph.D. | Chief Operating Officer and Chief Medical Officer |
| Ryker Willie | Senior Vice President of Finance and Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 22, 2024 | ARS | Filing |
| May 22, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 22, 2024 | DEF 14A | Other definitive proxy statements |
| May 17, 2024 | EFFECT | Notice of Effectiveness |
| May 17, 2024 | 424B3 | Prospectus |
| May 13, 2024 | 10-Q | Quarterly Report |
| May 10, 2024 | 8-K | Current Report |
| May 10, 2024 | D | Notice of Exempt Offering of Securities |
| May 8, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| May 3, 2024 | 8-K | Current Report |